According to Zacks, “IntriCon designs, develops, engineers and manufactures microminiaturized medical and electronic products. The Company supplies microminiaturized components, systems and molded plastic parts, primarily to the hearing instrument manufacturing industry, as well as the computer, government, electronics, telecommunications and medical equipment industries. The Company has facilities in the United States, Asia and Europe. “
Separately, ValuEngine cut Whiting USA Trust II from a hold rating to a sell rating in a research note on Tuesday, May 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $50.25.
IntriCon (NASDAQ:IIN) last released its quarterly earnings data on Monday, April 29th. The technology company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). IntriCon had a net margin of 4.58% and a return on equity of 7.39%. The business had revenue of $30.11 million during the quarter, compared to analyst estimates of $30.05 million. Equities research analysts forecast that IntriCon will post 0.58 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp lifted its position in IntriCon by 1.3% in the fourth quarter. Northern Trust Corp now owns 107,608 shares of the technology company’s stock valued at $2,839,000 after purchasing an additional 1,375 shares during the period. BNP Paribas Arbitrage SA acquired a new stake in IntriCon in the first quarter valued at about $40,000. Squarepoint Ops LLC lifted its position in IntriCon by 37.3% in the fourth quarter. Squarepoint Ops LLC now owns 11,555 shares of the technology company’s stock valued at $305,000 after purchasing an additional 3,138 shares during the period. Rhumbline Advisers lifted its position in IntriCon by 58.9% in the fourth quarter. Rhumbline Advisers now owns 9,104 shares of the technology company’s stock valued at $240,000 after purchasing an additional 3,375 shares during the period. Finally, US Bancorp DE lifted its position in IntriCon by 6.4% in the first quarter. US Bancorp DE now owns 60,344 shares of the technology company’s stock valued at $1,513,000 after purchasing an additional 3,650 shares during the period. 72.51% of the stock is currently owned by hedge funds and other institutional investors.
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.
See Also: How Investors Use a Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.